Mirum Pharmaceuticals (MIRM) has drawn fresh attention after presenting late breaking Phase 2b data for volixibat in primary sclerosing cholangitis and brelovitug in hepatitis delta virus, alongside regulatory progress toward a planned volixibat New Drug Application.

The recent late breaking trial results arrive after a year where Mirum’s share price return is up 27.5% year to date, while the 1 year total shareholder return is 103.06%. This suggests momentum has picked up despite a 6.87% decline in the 1 month share price return.

If this kind of clinical progress interests you, it could be a good time to broaden your watchlist with rare disease peers using the 40 healthcare AI stocks

With Mirum’s stock reportedly up strongly over 1 and 3 years and trading at a reported intrinsic discount of about 76%, the key question is whether this reflects an opportunity or if the market is already pricing in future growth.

Most Popular Narrative: 30.9% Undervalued

With Mirum Pharmaceuticals last closing at $99.54 against a narrative fair value of $144.15, the current setup hinges heavily on how its rare disease pipeline plays out.

Multiple late-stage pipeline catalysts, including three pivotal study readouts (VISTAS, VANTAGE, EXPAND) over the next 24 months and the initiation of the Phase II Fragile X study, set the stage for further product label expansions and new indication launches, underpinning future revenue diversification and potential earnings acceleration.

Curious what kind of revenue ramp, margin shift, and future earnings multiple are baked into that fair value? The narrative leans on bold growth, rising profitability, and a rich future valuation multiple that assumes Mirum starts to look more like a scaled rare disease leader than an early stage loss maker.

Result: Fair Value of $144.15 (UNDERVALUED)

However, the story can change quickly if Livmarli faces tougher competition or reimbursement pushback, or if key late stage trials fail to deliver as expected.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With sentiment split between the upside potential and the risks flagged in our work, move quickly to review the details and shape your own view with the 3 key rewards and 2 important warning signs

Ready for more investment ideas?

If you only stick with one stock, you risk missing other opportunities that fit your style, so put a few more ideas on your radar today.

• Target potential mispricings by scanning 46 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their underlying strength.
• Prioritise resilience by checking 67 resilient stocks with low risk scores that score well on financial stability so you are not surprised when conditions change.
• Hunt for fresh opportunities by reviewing the screener containing 20 high quality undiscovered gems that other investors may not be watching yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.